

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Zichria ZAKAY-RONES et al.

Confirmation No.: 1732

Application No.: 10/800,256

Patent No.: 7,223,389 B2

Filing Date: March 11, 2004

Patent Date: May 29, 2007

For: COMPOSITIONS AND METHODS FOR
TREATMENT OF CANCER

Attorney Docket No.: 85189-5900

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.322

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Patentees hereby respectfully request the issuance of a Certificate of Correction in connection with the above-identified patent. The corrections are listed on the attached Form PTO-1050. The corrections requested are as follows:

Column 39:

Line 45 (claim 1, line 1), after “An isolated”, insert -- clonal --. Support for this change appears in application claim 1.

Line 65 (claim 5, line 4), after “to claim”, delete “3” and insert -- 2 --. Support for this change appears in application claim 24.

Column 40:

Line 60 (claim 10, line 2), after “according to claim”, delete “3” and insert -- 2 --. Support for this change appears in application claim 55.

The requested corrections are for errors that appear to have been made by the Office. Therefore, no fee is believed to be due for this request. Should any fees be required, however, please charge such fees to Winston & Strawn LLP Deposit Account No. 50-1814. Please issue a Certificate of Correction in due course.

Respectfully submitted,

6-5-07

Date



Allan A. Fanucci, Reg. No. 30,256

WINSTON & STRAWN LLP
Customer No. 28765

212-294-3311

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

PATENT NO.: 7,223,389 B2

Page 1 of 1

APPLICATION NO.: 10/800,256

DATED: May 29, 2007

INVENTORS: Zakay-Rones et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 39:

Line 45 (claim 1, line 1), after "An isolated", insert -- clonal --.

Line 65 (claim 5, line 4), after "to claim", delete "3" and insert -- 2 --.

Column 40:

Line 60 (claim 10, line 2), after "according to claim", delete "3" and insert -- 2 --.

-continued

<210> SEQ ID NO 31
 <211> LENGTH: 21
 <212> TYPE: DNA
 <213> ORGANISM: Newcastle disease virus
 <400> SEQUENCE: 31

tgatgcatg agcactggct g

21

<210> SEQ ID NO 32
 <211> LENGTH: 19
 <212> TYPE: DNA
 <213> ORGANISM: Newcastle disease virus
 <400> SEQUENCE: 32

ttgcagctgc aggaattgt

19

<210> SEQ ID NO 33
 <211> LENGTH: 22
 <212> TYPE: DNA
 <213> ORGANISM: Newcastle disease virus
 <400> SEQUENCE: 33

ctatacagta tgagggtcca ag

22

<210> SEQ ID NO 34
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Newcastle disease virus
 <400> SEQUENCE: 34

gaattgacta cagattatgg

20

<210> SEQ ID NO 35
 <211> LENGTH: 17
 <212> TYPE: DNA
 <213> ORGANISM: Newcastle disease virus
 <400> SEQUENCE: 35

gagcgggtcca tgattga

17

The invention claimed is:

1. An isolated lentogenic oncolytic strain of Newcastle Disease Virus (NDV) comprising the DNA nucleotide sequence of SEQ ID NO: 1 encoding for the fusion (F) gene and at least part of the hemagglutinin-neuraminidase (HN) gene.

2. A pharmaceutical composition for the treatment of cancer comprising the clonal lentogenic oncolytic strain of Newcastle Disease Virus (NDV) according to claim 1, optionally in combination with a suitable carrier.

3. The pharmaceutical composition according to claim 2 wherein the carrier is present.

4. The pharmaceutical composition according to claim 2 wherein the strain is present in an amount of 10^6 – 10^{12} EID₅₀ per unit dose.

5. A method for treating cancer in a patient comprising administering to the patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 3.

6. The method of claim 5 wherein the step of administering is selected from intravenous, oral, buccal, intranasal,

inhalation, topical application to a mucosal membrane or injection, including intradermal, intrathecal, intracisternal, and intralesional injection.

7. The method of claim 5 wherein the step of administering comprises locally administering the composition to a tumor or in its vicinity.

8. The method of claim 5 wherein the strain is present in the composition in an amount of 10^6 – 10^{12} EID₅₀ per unit dose.

9. The method of claim 5 wherein the step of administering comprises administering the strain of NDV in a range of 20 EID₅₀/cell to 2000 EID₅₀/cell.

10. A method of making the pharmaceutical composition according to claim 3 which comprises incorporating in the composition the clonal lentogenic oncolytic strain of Newcastle Disease Virus (NDV) comprising the DNA nucleotide sequence of SEQ ID NO: 1 encoding for the fusion (F) gene and at least part of the hemagglutinin-neuraminidase (HN).

* * * * *